Risks and benefits of stress ulcer prophylaxis for patients with severe sepsis

Critical Care Medicine

Volumn 44, Issue 7, 2016, Pages e464-e469

  Sasabuchi, Yusuke ^a   Matsui, Hiroki ^a   Lefor, Alan K ^b   Fushimi, Kiyohide ^c   Yasunaga, Hideo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Clostridium difficile infection; gastrointestinal bleeding; hospital acquired pneumonia; severe sepsis; stress ulcer prophylaxis

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; HYPERTENSIVE FACTOR; INOTROPIC AGENT; PROTON PUMP INHIBITOR; ANTICOAGULANT AGENT; HEPARIN;

ARTICLE; ARTIFICIAL VENTILATION; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ENDOSCOPIC HEMOSTASIS; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; STRESS ULCER; AGED; COMPLICATION; FACTUAL DATABASE; FEMALE; MALE; MIDDLE AGED; PEPTIC ULCER; RISK ASSESSMENT;

AGED; ANTICOAGULANTS; DATABASES, FACTUAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPARIN; HISTAMINE H2 ANTAGONISTS; HUMANS; JAPAN; MALE; MIDDLE AGED; PEPTIC ULCER; PROPENSITY SCORE; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEPSIS;

EID: 84961390867     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001667     Document Type: Article

References (34)

1. Dombrovskiy VY, Martin AA, Sunderram J, et al. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit Care Med 2007; 35:1244-1250
2. Kumar G, Kumar N, Taneja A, et al; Milwaukee Initiative in Critical Care Outcomes Research Group of Investigators: Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest 2011; 140:1223-1231
3. Bouza C, Lopez-Cuadrado T, Saz-Parkinson Z, et al. Epidemiology and recent trends of severe sepsis in Spain: A nationwide populationbased analysis (2006-2011). BMC Infect Dis 2014; 14:717
4. Shen HN, Lu CL, Yang HH. Epidemiologic trend of severe sepsis in Taiwan from 1997 through 2006. Chest 2010; 138:298-304
5. Caironi P, Tognoni G, Masson S, et al; ALBIOS Study Investigators: Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014; 370:1412-1421
6. Gaieski DF, Edwards JM, Kallan MJ, et al. The relationship between hospital volume and mortality in severe sepsis. Am J Respir Crit Care Med 2014; 190:665-674
7. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
8. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
9. Lindenauer PK, Rothberg MB, Nathanson BH, et al. Activated protein C and hospital mortality in septic shock: A propensity-matched analysis. Crit Care Med 2010; 38:1101-1107
10. Cook DJ, Griffith LE, Walter SD, et al; Canadian Critical Care Trials Group: The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001; 5:368-375
11. Dellinger RP, Carlet JM, Masur H, et al; Surviving Sepsis Campaign Management Guidelines Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
12. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637
13. Pinilla JC, Oleniuk FH, Reed D, et al. Does antacid prophylaxis prevent upper gastrointestinal bleeding in critically ill patients?. Crit Care Med 1985; 13:646-650
14. Tryba M. Prevention of stress bleeding with ranitidine or pirenzepine and the risk of pneumonia. J Clin Anesth 1988; 1:12-20
15. Basso N, Bagarani M, Materia A, et al. Cimetidine and antacid prophylaxis of acute upper gastrointestinal bleeding in high risk patients. Controlled, randomized trial. Am J Surg 1981; 141:339-341
16. Bresalier RS, Grendell JH, Cello JP, et al. Sucralfate suspension versus titrated antacid for the prevention of acute stress-related gastrointestinal hemorrhage in critically ill patients. Am J Med 1987; 83:110-116
17. Cheadle WG, Vitale GC, Mackie CR, et al. Prophylactic postoperative nasogastric decompression. A prospective study of its requirement and the influence of cimetidine in 200 patients. Ann Surg 1985; 202:361-366
18. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170:784-790
19. Yamana H, Matsui H, Sasabuchi Y, et al. Categorized diagnoses and procedure records in an administrative database improved mortality prediction. J Clin Epidemiol 2015; 68:1028-1035
20. Matsuda S, Fujimori K, Kuwabara K, et al. Diagnosis procedure combination as an infrastructure for the clinical study. Asian Pac J Dis Manag 2011; 5:81-87
21. Iwagami M, Yasunaga H, Doi K, et al. Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: A propensity-matched analysis. Crit Care Med 2014; 42:1187-1193
22. Sasabuchi Y, Yasunaga H, Matsui H, et al. The volume-outcome relationship in critically ill patients in relation to the ICU-To-hospital bed ratio. Crit Care Med 2015; 43:1239-1245
23. Sundararajan V, Macisaac CM, Presneill JJ, et al. Epidemiology of sepsis in Victoria, Australia. Crit Care Med 2005; 33:71-80
24. Eddleston JM, Pearson RC, Holland J, et al. Prospective endoscopic study of stress erosions and ulcers in critically ill adult patients treated with either sucralfate or placebo. Crit Care Med 1994; 22: 1949-1954
25. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43:1130-1139
26. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28:3083-3107
27. Krag M, Perner A, Wetterslev J, et al. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-Analysis and trial sequential analysis. Intensive Care Med 2014; 40:11-22
28. Marik PE, Vasu T, Hirani A, et al. Stress ulcer prophylaxis in the new millennium: A systematic review and meta-Analysis. Crit Care Med 2010; 38:2222-2228
29. Alaniz C, Hyzy RC. Albumin meta-Analysis and epochs of care. Crit Care Med 2011; 39:1852
30. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-Acquired Clostridium difficile-Associated disease. JAMA 2005; 294:2989-2995
31. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-Associated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-1260
32. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372:1539-1548
33. Miyaji T, Sha M, Hirose M. Nationwide study of ventilator management and maintenance in Japan. Jpn J Respir Care 2006; 23:92-97
34. Takinami M, Uchino S, Kase Y, et al. Current management for clinically ill patients with mechanical ventilation on the ward. J Jpn Soc Intensive Care Med 2011; 18:417-418